Navigation Links
Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
Date:10/11/2010

SAN DIEGO, Oct. 11 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced two oral presentations from studies related to lead developmental product candidate, fidaxomicin, will be presented at the 48th Annual Meeting of the Infectious Disease Society of America (IDSA) to be held at the Vancouver Convention Center in Vancouver, British Columbia, Canada on October 21-24, 2010.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)"Efficacy and Safety of Fidaxomicin vs. Vancomycin in Clostridium difficile Infection in 2 Randomized Controlled Trials with 1105 Patients"Oral Presentation: Derrick Crook, M.D.Saturday, October 23, 2010 3:30pm Pacific TimeSession: 146 Oral Abstract Session: Clostridium difficilePresentation number: 1417 "Categorization of Patients in a Large Multicenter Study of Clostridium difficile Infection Using the ATLAS Bedside Scoring System, and Correlation with Both Cure and Recurrence"Oral Presentation: Mark A. Miller, M.D.Saturday, October 23, 2010 2:00pm Pacific TimeSession: 146 Oral Abstract Session: Clostridium difficilePresentation number: 1411About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates under development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI)
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
3. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
7. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
8. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
10. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... LOS ANGELES , May 5, 2015 ... and pioneer in providing on-demand access to scientific, technical ... purchasing agreement with the Association of Southeastern Research ... of 38 research libraries located across 11 southeastern states. ... developing innovative and collaborative programs to address the continually ...
(Date:5/5/2015)... , May 5, 2015  A group of biotechnology ... the Coma Research Institute, a non-profit organization dedicated to ... families suffering from disorders of consciousness.  ... http://photos.prnewswire.com/prnh/20150504/213779LOGO   ... consciousness, in which no voluntary actions can be initiated ...
(Date:5/5/2015)... Franz Inc ., the leading supplier of ... product, AllegroGraph, has been named a Champion by Bloor Research ... AllegroGraph is a high performance Semantic Graph Database that ... are skyrocketing in popularity and have grown by 400% in ... ranking by DB-Engines. , “We are excited that Graph ...
(Date:5/5/2015)... 05, 2015 Research and Markets ... the "Clinical Laboratory, Molecular Diagnostics and Genomic ... 2019 - Europe Version" report to their ... the area of molecular diagnostics and pharmacogenics hold ... world market that is moving out of the ...
Breaking Biology Technology:Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 2Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 3Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 4Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 4Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 5Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 2Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 3European Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market 2015-2019 2
... UPPSALA, Sweden, May 25 Beactica AB, the ... has entered,into an agreement with Cubist Pharmaceuticals, Inc. ... agreement, Beactica will use its Sprint(TM) surface plasmon,resonance ... pathogenic bacteria of interest to Cubist. Financial terms ...
... further promote young researchers in Germany, the Deutsche ... new Research Training Groups. This has just been ... DFG in Bonn. The new Research Training Groups ... doctorates in a structured research and qualification programme ...
... OMAHA, Neb., May 22 Transgenomic, Inc. (OTC Bulletin ... Schuh, Ph.D. and Michael B. McNulty to its Board ... Executive Officer of Sorrento Therapeutics, Inc. (STI). STI ... antibody library construction technology, the STI technology, which applies ...
Cached Biology Technology:DFG establishes 14 new research training groups 2DFG establishes 14 new research training groups 3DFG establishes 14 new research training groups 4DFG establishes 14 new research training groups 5DFG establishes 14 new research training groups 6DFG establishes 14 new research training groups 7Transgenomic, Inc. Announces Appointment of New Board Members 2Transgenomic, Inc. Announces Appointment of New Board Members 3
(Date:3/23/2015)... 23, 2015  In the 2014 fiscal year, irs.gov ... losses. This figure accounts for a fraction of the ... Nilson Report, exceeds $11 billion globally. The polygraph has ... crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test in ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ) ... Sensors Market Forecast and Opportunities 2020" report ... is projected to grow at a CAGR over ... industrial and healthcare sectors are the key application ... adoption of MEMS technology in sensors is growing ...
(Date:3/20/2015)... March 20, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... one of the products featured in 2015 "I Want ... 11:00 PM EST on the DIY Network.   ... Las Vegas , site of the 2015 International ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... that bigger, stronger, faster organisms have a distinct advantage ... a given community. But new research from the ... organisms increase their chances of survival if they evolve ... as well, a sort of "survival of the weakest." ...
... premier cancer congress: The 2011 European Multidisciplinary Cancer ... 2011 European Multidisciplinary Cancer Congress will take place ... ( www.stofair.se ) from Friday 23 September to ... build on the success of the previous ECCO ...
... a collection of test tubes in her Iowa State University ... were holding very weak coffee. That meant microorganisms in ... sugars into hydrocarbons, said Jarboe, an Iowa State assistant professor ... sugars in those test tubes were produced by the fast ...
Cached Biology News:Bacteria develop restraint for survival in a rock-paper-scissors community 2European Multidisciplinary Cancer Congress 2011 2Iowa State hybrid lab combines technologies to make biorenewable fuels and products 2Iowa State hybrid lab combines technologies to make biorenewable fuels and products 3
... Cloning Kits are designed to speed up the ... PCR products, regardless of sequence or type of ... including those that are difficult to clone by ... unstable or code for potentially detrimental proteins can ...
Size & Applications: 20 ml Storage Temp.: -20C Shelf Life: 12 months ...
PCR System for increased fidelity, yield and length of PCR products. Amplifies targets up to 10 kb from human genomic DNA....
Immunogen: Heat inactivated bacterial cells of Salmonella enteriditis,paratyphi and typhimurium Storage: 4 C...
Biology Products: